Ibuprofen Kabi (Ibuprofen)

Ibuprofen works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2. This inhibition reduces the production of prostaglandins, which are mediators of pain, fever, and inflammation, thereby providing relief from these symptoms.

The dose of Ibuprofen Kabi is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and overall clinical assessment. No fixed regimen is provided here; the prescriber sets the appropriate dosage and infusion rate.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk, and a healthcare professional should be consulted before administration to pregnant or nursing individuals.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with oral ibuprofen, the intravenous form offers rapid onset and predictable plasma levels, useful in patients unable to take oral medication. Relative to ketorolac, another injectable NSAID, ibuprofen has a slightly longer half‑life and a broader safety margin for gastrointestinal irritation, though both share similar renal and cardiovascular cautions.

Ibuprofen Kabi must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

The medication is given by intravenous infusion. The healthcare professional selects an appropriate infusion set, dilutes the solution if required, and administers it over the prescribed time period, typically ranging from a few minutes to an hour, under aseptic conditions.

Serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored closely for signs of bleeding, renal dysfunction, or allergic reactions during therapy.

Ibuprofen Kabi is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, severe renal impairment, and in the third trimester of pregnancy. Caution is also advised for individuals with uncontrolled hypertension or significant cardiovascular disease.